PharmaNet Going Private (PDGI)

Banking, finance, and taxes

Published: February 3, 2009 8:42 am

Last Updated: April 28, 2020 3:36 am

Money_stack_pic This may be far from a super-merger and may be far from a return or thrust from private equity. But it is a deal in the drug and research sector. PharmaNet Development Group, Inc. (NASDAQ: PDGI) has agreed to be acquired by JLL Partners, Inc.

JLL will commence a tender offer topurchase all of the outstanding shares of PharmaNet fot$5.00per share in cash. This is a huge premium when youconsider that the stock closed at $1.34 yesterday. But you also have tokeep in mind that the 52-week trading range of $0.67 to $42.77.

This values the company at roughly $100 million and will be financed bya $250 million equity commitment from JLL. This includes the necessaryfunds to retire the $144 million principal amount of outstandingconvertible notes.

The transaction is subject to the valid tender of a majority ofPharmaNet common stock, regulatory approvals and other customaryconditions

Assuming all goes as planned, the tender offer is expected to close bythe end of the first quarter. That implies less than 60 days fromnow. Shares were halted for trading and are set to resume at 9:00 AMEST.

Jon C. Ogg
February 3, 2009

Credit Card Companies Are Doing Something Nuts

Credit card companies are at war. The biggest issuers are handing out free rewards and benefits to win the best customers.

It’s possible to find cards paying unlimited 1.5%, 2%, and even more today. That’s free money for qualified borrowers, and the type of thing that would be crazy to pass up. Those rewards can add up to thousands of dollars every year in free money, and include other benefits as well.

We’ve assembled some of the best credit cards for users today. Don’t miss these offers because they won’t be this good forever.

Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.